Teoxane Launches babyGLOW™ in the UK Following IMCAS 2026 Debut

Teoxane has officially launched its new babyGLOW™ technique in the UK and Ireland.

The disruptive new protocol was first unveiled during Teoxane’s dedicated symposium at IMCAS 2026 and has been developed in collaboration with a collective of more than 15 international aesthetic medicine experts.

Inspired by makeup contouring and highlighting techniques, babyGLOW™ by Teoxane has been designed as a standardised, anatomy-based injection protocol focused on enhancing skin radiance, hydration and overall skin quality, without altering facial features or adding excessive volume.

The technique uses eight carefully selected facial injection points intended to optimise product diffusion and maximise surface light reflection, helping to create a brighter, fresher and more rested appearance from the first treatment session.

According to Teoxane, the protocol enhances facial luminosity, softens shadowed areas and gently lifts contours for improved balance and freshness.

At the centre of the treatment is TEOSYAL® Puresense Redensity 1, a non-crosslinked hyaluronic acid formulation combined with a Dermo Restructuring Complex containing antioxidants, amino acids, vitamins and minerals. The product’s high fluidity allows for homogeneous dermal and subdermal distribution, supporting skin redensification and hydration.

The launch reflects the growing industry movement toward skin quality-focused treatments and regenerative aesthetics, with practitioners increasingly prioritising natural-looking rejuvenation over volume-led correction.

Aesthetic practitioner Dr Silvia Caboni described babyGLOW™ as a versatile treatment suitable across multiple patient demographics.

“In younger patients, it has a preventive role by maintaining hydration and supporting skin quality,” she explained. “In more mature skin, the effect is more rejuvenating as it improves texture, redensifies thinner areas and stimulates collagen production.”

Joanna Underhill, General Manager for Teoxane UK & Ireland, said the company is “delighted” to bring the new technique to practitioners in the UK and Ireland, adding that the protocol offers both enhanced treatment efficiency and scientifically supported outcomes.

Dr Kieren Bong, Global Teoxane Faculty Member and babyGLOW™ Board Member, also highlighted the broader implications of the treatment for the future of aesthetic medicine.

“The aim was to develop a precise, reproducible injection technique that could deliver a consistent glow effect and genuine improvement in skin quality whilst preserving facial identity,” he said. “babyGLOW™ shifts the focus away from temporary surface improvement and towards true biological skin remodelling.”

He added that the technique represents a wider evolution within aesthetics toward tissue health, collagen support and long-term skin quality optimisation.

With demand continuing to grow for subtle, regenerative treatments that prioritise natural results, babyGLOW™ by Teoxane is expected to become a significant addition to the UK’s expanding skin quality treatment market.